- Departments, Labs and Institutes
- Research Centers and Programs
- Stem Cell Biology and Cellular Therapy Program
The focus of the Stem Cell Biology and Cellular Therapy Program (SCB) is to enhance the understanding of normal and malignant stem cell biology while developing and advancing novel cellular therapies for use for patients with hematologic malignancies or solid tumors.
The focus of the Stem Cell Biology and Cellular Therapy Program (SCB) is to enhance the understanding of normal and malignant stem cell biology while developing and advancing novel cellular therapies for use for patients with hematologic malignancies or solid tumors.
The three aims of the SCB program
The program will advance our understanding of stem cell, T cell and NK cell biology and to develop new T and NK cell therapies for liquid and solid tumors.
Aim 1
Normal and Malignant Stem Cell Biology
Elucidate the pre-malignant and malignant stem cell biology and model in cancers to develop innovative stem cell transplant modalities
Aim 2
T cell Biology and Therapeutics
Leverage understanding of T cell biology to develop novel interventions for cancer, including CAR T, TCR-like antibodies and T cell bispecific engagers
Aim 3
NK Cell Biology and Therapeutics
Develop novel NK cell platforms and leveraging bispecific NK engagers for liquid and solid tumors
Leadership
Elizabeth J. Shpall, M.D.
SCB Co-leader
Robert Z. Orlowski, M.D., Ph.D.
SCB Co-leader
Simona Colla, Ph.D.
SCB Associate Leader
Warren Fingrut, M.D.
SCB Cancer Research Training and Education Coordination Liaison
Chijoke Nze, M.D.
SCB Community Outreach and Engagement Liaison
SCB members regularly participate in the following activities
-
Hematopoietic Stem Cell and Myelodysplastic Syndromes Symposium
-
Institute for Cell Therapy Discovery & Innovation Seminar
-
Stem Cell Transplantation and Cellular Therapy Special Lecture
-
Stem Cell Transplantation and Cellular Therapy Seminar
-
Stem Cell Transplantation and Lymphoma/Myeloma Fellows Lecture
Featured Publications
CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3ζ/ZAP70 Signaling Axis
Cancer Discovery, 2024
Acharya S, Basar R, Daher M, Rafei H, Li P, Uprety N, Ensley E, Shanley M, Kumar B, Banerjee PP, Melo Garcia L, Lin P, Mohanty V, Kim KH, Jiang X, Pan Y, Li Y, Liu B, Nunez Cortes AK, Zhang C, Fathi M, Rezvan A, Montalvo MJ, Cha SL, Reyes-Silva F, Shrestha R, Guo X, Kundu K, Biederstädt A, Muniz-Feliciano L, Deyter GM, Kaplan M, Jiang XR, Liu E, Jain A, Roszik J, Fowlkes NW, Solis Soto LM, Raso MG, Khoury JD, Lin PEMP, Vega F, Varadarajan N, Chen K, Marin D, Shpall EJ, Rezvani K.
Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis
Science, 2021
Del Poggetto E, Ho IL, Balestrieri C, Yen EY, Zhang S, Citron F, Shah R, Corti D, Diaferia GR, Li CY, Loponte S, Carbone F, Hayakawa Y, Valenti G, Jiang S, Sapio L, Jiang H, Dey P, Gao S, Deem AK, Rose-John S, Yao W, Ying H, Rhim AD, Genovese G, Heffernan TP, Maitra A, Wang TC, Wang L, Draetta GF, Carugo A, Natoli G, Viale A
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy
Nature Medicine, 2022
Ganan-Gomez I, Yang H, Ma F, Montalban-Bravo GEMP, Thongon N, Marchica V, Richard-Carpentier G, Chien K, Manyam G, Wang F, Alfonso A, Chen S, Class C, Kanagal-Shamanna R, Ingram JP, Ogoti Y, Rose A, Loghavi S, Lockyer P, Cambo B, Muftuoglu M, Schneider S, Adema V, McLellan M, Garza J, Marchesini M, Giuliani N, Pellegrini M, Wang J, Walker J, Li Z, Takahashi K, Leverson JD, Bueso-Ramos C, Andreeff M, Clise-Dwyer K, Garcia-Manero G, Colla S
CCSG Research Programs
Give Now
Your gift will help make a tremendous difference.
Research Areas
Find out about the four types of research taking place at MD Anderson.
Subscribe
Get the latest information on our cancer breakthroughs.